Get the Stockscreener App
41.08
0.70%
-0.29
Pre-market:
40.98
-0.10
-0.24%
Qiagen Nv stock is traded at $41.08, with a volume of 1.65M.
It is down -0.70% in the last 24 hours and up +4.24% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$41.37
Open:
$41.43
24h Volume:
1.65M
Relative Volume:
0.64
Market Cap:
$8.47B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
21.22
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
+1.48%
1M Performance:
+4.24%
6M Performance:
-24.23%
1Y Performance:
-20.68%
1-Day Range:
$40.99
$41.66
1-Week Range:
$39.36
$41.66
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, NTRA
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
41.08 | 8.47B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
559.53 | 207.93B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.50 | 138.14B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
556.20 | 43.87B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
137.89 | 38.94B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
258.03 | 36.95B | 2.50B | -226.32M | 71.51M | -1.6412 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen Sees Unusually High Options Volume (NYSE:QGEN) - MarketBeat
Qiagen stock holds firm as diagnostics demand supports growth outlook - Ad-hoc-news.de
Qiagen NV (QGEN) Cash Flow - TradingKey
Qiagen NV (QGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Troluce Capital Advisors LLC Purchases Shares of 362,500 Qiagen N.V. $QGEN - MarketBeat
Sona Asset Management US LLC Invests $8.89 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. $QGEN Holdings Cut by Bank of New York Mellon Corp - MarketBeat
Qiagen stock trades steady as latest results highlight consumables growth and margin resilience - Ad-hoc-news.de
QGEN|Qiagen NV|Price:41.370|Chg%:-0.050 - TradingKey
Qiagen NV (QGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Qiagen NV (QGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Qiagen NV (QGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Qiagen stock trades steady as diagnostics demand supports revenue growth - Ad-hoc-news.de
Bessemer Group Inc. Sells 43,977 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steadily as investors weigh Q2 2026 earnings and molecular diagnostics growth - Ad-hoc-news.de
BlackRock builds 11.6% stake in Qiagen, lifting voting power to 13% - The Globe and Mail
Qiagen stock trades steady as investors weigh Q2 2026 revenue momentum and margin trends - Ad-hoc-news.de
Sei Investments Co. Decreases Stock Holdings in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steady as investors weigh recent earnings and diagnostics demand - Ad-hoc-news.de
Qiagen stock stays supported as molecular testing demand underpins growth - Ad-hoc-news.de
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock steadies as investors await fresh numbers - AD HOC NEWS
Does Qiagen's Expanded QIAstat-Dx Infection and AMR Menu Reframe the Bull Case for QGEN? - simplywall.st
Qiagen stock trades steadily as molecular diagnostics growth supports margins - Ad-hoc-news.de
Qiagen N.V. $QGEN Shares Acquired by Swiss National Bank - MarketBeat
Capula Management Ltd Purchases New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen NV (QGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Qiagen stock steadies as latest results highlight margin resilience and cash flow strength - AD HOC NEWS
AFM Filing Reveals BlackRock Builds Significant Stake in Qiagen - The Globe and Mail
Qiagen stock trades steadily as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
Qiagen stock holds steady as 2025 revenue and profit metrics frame the setup - Ad-hoc-news.de
Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock steadies as investors weigh recent earnings and molecular diagnostics growth - Ad-hoc-news.de
KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen - Yahoo Finance
Qiagen stock trades steady as diagnostics revenue grows and margin focus intensifies - Ad-hoc-news.de
Qiagen stock trades steady as diagnostics demand supports earnings momentum - AD HOC NEWS
Barclays lifts QIAGEN voting rights stake to 3.19% - Bitget
Qiagen stock trades steady as diagnostics demand supports recent earnings - AD HOC NEWS
Qiagen stock holds firm as diagnostics demand supports revenue growth - Ad-hoc-news.de
Qiagen stock trades steady as recent results highlight margin resilience - Ad-hoc-news.de
Qiagen stock rises on recent results and market data - Ad-hoc-news.de
Baader Bank Aktiengesellschaft Buys New Stake in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock trades steadily as diagnostics demand supports earnings and cash flow - Ad-hoc-news.de
Qiagen stock trades steadily as recent earnings and margin trends shape investor focus - Ad-hoc-news.de
Qiagen N.V. (QGEN) Stock Analysis: Evaluating The 7.09% Upside Potential For Investors - DirectorsTalk Interviews
DekaBank Deutsche Girozentrale Takes $10.81 Million Position in Qiagen N.V. $QGEN - MarketBeat
Qiagen stock holds as investors await fresh numbers - Ad-hoc-news.de
Qiagen stock trades steady as latest quarterly numbers highlight margin resilience - Ad-hoc-news.de
William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating - Moomoo
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
2.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):